JRI vs MA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile for JRI is critically weak, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental deterioration. While the fund offers an attractive dividend yield of 12.51%, the 90% payout ratio suggests limited sustainability and potential capital erosion. The current price of $12.81 trades at a premium to the growth-based intrinsic value of $12.32, and the technical trend is completely bearish (0/100). Overall, the combination of poor financial health scores and negative price momentum outweighs the high yield.
MA shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
JRI vs MA: Head-to-Head Comparison
This page compares Nuveen Real Asset Income and Growth Fund (JRI) and Mastercard Incorporated (MA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.